Insider Selling: Penumbra, Inc. (NYSE:PEN) EVP Sells 600 Shares of Stock

Penumbra, Inc. (NYSE:PENGet Free Report) EVP Johanna Roberts sold 600 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $207.41, for a total transaction of $124,446.00. Following the completion of the sale, the executive vice president now owns 63,488 shares in the company, valued at approximately $13,168,046.08. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Johanna Roberts also recently made the following trade(s):

  • On Monday, April 1st, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $217.07, for a total value of $130,242.00.
  • On Friday, March 1st, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $237.68, for a total transaction of $142,608.00.

Penumbra Stock Down 1.9 %

PEN traded down $3.99 during trading on Wednesday, reaching $204.74. The stock had a trading volume of 295,161 shares, compared to its average volume of 349,368. The company has a current ratio of 6.12, a quick ratio of 3.51 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $7.94 billion, a price-to-earnings ratio of 86.39, a P/E/G ratio of 2.08 and a beta of 0.57. The stock’s 50 day moving average is $218.24 and its two-hundred day moving average is $232.30. Penumbra, Inc. has a one year low of $180.93 and a one year high of $348.67.

Penumbra (NYSE:PENGet Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.01). The business had revenue of $278.70 million for the quarter, compared to analysts’ expectations of $274.94 million. Penumbra had a net margin of 8.52% and a return on equity of 7.83%. The company’s revenue was up 15.5% on a year-over-year basis. During the same period last year, the business earned $0.23 earnings per share. As a group, analysts expect that Penumbra, Inc. will post 2.87 earnings per share for the current year.

Institutional Investors Weigh In On Penumbra

Hedge funds have recently added to or reduced their stakes in the stock. Fifth Third Bancorp increased its holdings in Penumbra by 13.9% in the 4th quarter. Fifth Third Bancorp now owns 378 shares of the company’s stock worth $95,000 after buying an additional 46 shares in the last quarter. Signaturefd LLC grew its position in Penumbra by 27.2% in the 4th quarter. Signaturefd LLC now owns 215 shares of the company’s stock worth $54,000 after purchasing an additional 46 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Penumbra by 171.8% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 106 shares of the company’s stock valued at $27,000 after buying an additional 67 shares during the period. Treasurer of the State of North Carolina grew its holdings in shares of Penumbra by 0.4% in the third quarter. Treasurer of the State of North Carolina now owns 16,394 shares of the company’s stock worth $3,966,000 after acquiring an additional 70 shares during the period. Finally, M&T Bank Corp grew its stake in shares of Penumbra by 6.1% during the 3rd quarter. M&T Bank Corp now owns 1,262 shares of the company’s stock valued at $305,000 after purchasing an additional 72 shares during the period. 88.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PEN. Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a research report on Wednesday, May 8th. Truist Financial cut their price objective on Penumbra from $290.00 to $280.00 and set a “buy” rating for the company in a report on Friday, March 22nd. Piper Sandler dropped their target price on Penumbra from $290.00 to $260.00 and set an “overweight” rating for the company in a research report on Wednesday, May 8th. Canaccord Genuity Group cut their target price on Penumbra from $284.00 to $272.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Finally, JPMorgan Chase & Co. downgraded shares of Penumbra from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $284.00 to $250.00 in a research note on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $300.64.

Check Out Our Latest Stock Report on Penumbra

Penumbra Company Profile

(Get Free Report)

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

Featured Stories

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.